When do the patents on CORDARONE expire, and when will generic CORDARONE be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Pharms Inc	CORDARONE	amiodarone hydrochloride	INJECTABLE;INJECTION	020377-001	Aug 3, 1995		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Wyeth Pharms	CORDARONE	amiodarone hydrochloride	TABLET;ORAL	018972-001	Dec 24, 1985		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

Executive Summary

Cordarone, the brand name for amiodarone hydrochloride, is an antiarrhythmic drug classified as a Class III antiarrhythmic agent. It is primarily prescribed for the treatment of ventricular and supraventricular arrhythmias. The drug's market is characterized by established generic competition and a well-defined therapeutic niche. Key factors influencing its investment profile include patent expiry, generic market penetration, regulatory status, and the ongoing demand for antiarrhythmic therapies. This analysis evaluates the current investment landscape for Cordarone, considering its foundational pharmacology, patent history, market dynamics, and future outlook.

What is Cordarone and How Does It Work?

Cordarone (amiodarone hydrochloride) is a potent antiarrhythmic medication belonging to the Vaughan Williams classification of Class III antiarrhythmics. Its mechanism of action is complex and multimodal, affecting multiple ion channels crucial for cardiac electrical activity.

Potassium Channel Blockade: Amiodarone is a potent blocker of delayed rectifier potassium currents (IKr and IKs). This blockade prolongs the repolarization phase of the cardiac action potential and increases the effective refractory period of atrial and ventricular tissues. This is its primary Class III effect.
Sodium Channel Blockade: The drug also exhibits moderate blockade of voltage-gated sodium channels (INa), particularly in their inactivated state. This effect slows the rate of depolarization (Phase 0) of the action potential, particularly at faster heart rates, contributing to its anti-tachycardic properties.
Calcium Channel Blockade: Amiodarone weakly blocks L-type calcium channels, which can lead to a reduction in sinoatrial (SA) and atrioventricular (AV) nodal conduction.
Beta-Adrenergic Receptor Blockade: The drug possesses non-competitive beta-adrenergic receptor blocking properties, contributing to slowing of the heart rate and AV nodal conduction.

These combined actions result in stabilization of cardiac membranes, suppression of abnormal electrical activity, and a reduction in the risk of potentially fatal arrhythmias such as ventricular tachycardia and fibrillation, as well as certain supraventricular tachycardias.

What is the Patent and Regulatory History of Cordarone?

The foundational patent for amiodarone hydrochloride has long expired, leading to the availability of generic versions. The original patent was filed by the Belgian pharmaceutical company UCB Pharma.

Original Patent Filing: The initial patents protecting amiodarone were granted in the late 1960s and early 1970s. For example, a key patent was filed in 1969.
Market Exclusivity: With the expiration of these foundational patents, the market for amiodarone has been open to generic competition for several decades.
Regulatory Approvals: Amiodarone is approved by major regulatory bodies worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The initial FDA approval for Cordarone was granted in 1985 [1].
Post-Marketing Surveillance: Like many established drugs with a long history of use, amiodarone is subject to ongoing post-marketing surveillance and pharmacovigilance due to its potential for serious adverse effects, particularly pulmonary toxicity, hepatotoxicity, and thyroid dysfunction.

The absence of current patent protection for the active pharmaceutical ingredient (API) amiodarone hydrochloride means that market exclusivity is driven by formulation patents, manufacturing process patents, or specific indications, which are less common for a drug of this age and widespread generic availability.

What are the Market Dynamics for Cordarone?

The market for amiodarone is mature, characterized by significant generic penetration and a stable, albeit not rapidly growing, demand.

Generic Competition: Multiple pharmaceutical companies manufacture and market generic versions of amiodarone hydrochloride. This intense competition has driven down prices, limiting the profitability of brand-name Cordarone.
Therapeutic Niche: Amiodarone remains a critical treatment option for certain severe and refractory arrhythmias where other agents may be less effective or tolerated. Its broad spectrum of activity and proven efficacy in certain life-threatening conditions ensure its continued use.
Market Size and Growth: The global amiodarone market is estimated to be in the hundreds of millions of dollars annually. Growth in this market is largely driven by the aging global population, leading to an increased incidence of cardiovascular diseases, rather than significant therapeutic advancements or new market entrants. Projections indicate a modest compound annual growth rate (CAGR) in the low single digits.
Key Market Drivers:
- Prevalence of atrial fibrillation and ventricular arrhythmias.
- Use in acute settings (e.g., emergency management of ventricular arrhythmias).
- Indication for prophylaxis of symptomatic ventricular tachycardia.
Key Market Restraints:
- Significant and well-documented adverse effects requiring careful patient monitoring.
- Availability of alternative antiarrhythmic agents and newer therapeutic modalities (e.g., catheter ablation, pacemakers, implantable cardioverter-defibrillators (ICDs)).
- Intense price pressure from generic manufacturers.
Geographic Distribution: The demand is globally distributed, with significant markets in North America, Europe, and increasingly in Asia-Pacific regions due to rising cardiovascular disease rates.

Who are the Key Players in the Cordarone Market?

The market for amiodarone is dominated by generic manufacturers and distributors. While the original innovator, UCB Pharma, still markets Cordarone in some regions, its market share has been significantly eroded by generic alternatives.

Brand Name Manufacturer:
- Sanofi (formerly Sanofi-Aventis): Markets the brand-name Cordarone in many regions.
Major Generic Manufacturers:
- Teva Pharmaceuticals
- Mylan N.V. (now part of Viatris)
- Sun Pharmaceutical Industries
- Dr. Reddy's Laboratories
- Aurobindo Pharma
- Lupin Limited
Key Distributors: Pharmaceutical wholesalers and distributors play a critical role in supplying generic amiodarone to pharmacies and hospitals worldwide.

The competitive landscape is highly fragmented, with numerous generic players vying for market share based on price, supply chain reliability, and regulatory compliance.

What are the Risks and Opportunities for Cordarone Investments?

Investing in a mature, genericized drug like amiodarone presents a specific risk-reward profile.

Risks

Price Erosion: Ongoing generic competition inherently leads to downward pressure on pricing, limiting profit margins.
Adverse Event Profile: The serious and potentially life-threatening side effects (e.g., pulmonary fibrosis, thyroid dysfunction, hepatotoxicity) necessitate strict patient monitoring and can lead to reduced prescribing in favor of agents with better safety profiles where appropriate. This can dampen demand growth.
Therapeutic Advancements: The development of new antiarrhythmic drugs or non-pharmacological interventions like advanced catheter ablation techniques and improved ICDs could further displace amiodarone in certain patient populations.
Regulatory Scrutiny: While not new, ongoing pharmacovigilance and potential for updated safety warnings or usage restrictions can impact market access and prescription patterns.
Supply Chain Disruptions: As with any pharmaceutical product, reliance on global API manufacturers and complex supply chains can introduce risks related to raw material availability, manufacturing issues, or geopolitical events.

Opportunities

Established Efficacy and Indication Breadth: Amiodarone remains a cornerstone therapy for specific, severe arrhythmias where its risk-benefit profile is favorable and alternatives are limited or less effective. This ensures a baseline level of demand.
Cost-Effectiveness: Generic amiodarone is a highly cost-effective treatment option, particularly in healthcare systems with budget constraints. This makes it a preferred choice for many indications, especially in broad-based treatment protocols.
Emerging Market Growth: Increasing access to healthcare and a growing prevalence of cardiovascular diseases in emerging economies can drive incremental volume growth for established, affordable generics.
Specialty Formulations or Delivery Systems: While less common for older drugs, there is a theoretical opportunity for innovation in novel formulations or delivery systems that might improve the safety profile or patient compliance, though such developments are unlikely to significantly alter the market dynamics for amiodarone API.
Acquisition Targets: Companies with strong generic manufacturing capabilities and robust distribution networks may find amiodarone products to be valuable additions to their portfolios, particularly if they can achieve economies of scale or optimize supply chains.

What is the Future Outlook for Cordarone?

The future outlook for amiodarone is one of sustained, albeit modest, demand within its established therapeutic niche, rather than significant growth or innovation.

Continued Prescribing for Severe Arrhythmias: Amiodarone will likely remain a critical drug for patients with refractory ventricular arrhythmias, certain types of supraventricular tachycardia, and as a treatment for patients who have failed other therapies. Its role in acute settings for the management of life-threatening arrhythmias is secure.
Increased Competition and Price Pressure: The generic nature of the drug means that competition will remain fierce, and pricing will continue to be a dominant factor. Companies that can achieve high manufacturing efficiency and maintain reliable supply chains will be best positioned.
Focus on Safety Monitoring: Healthcare providers will continue to emphasize the importance of close patient monitoring to manage amiodarone's significant adverse effects. This could lead to more judicious use in certain patient populations where less toxic alternatives exist.
Role in Combination Therapies: Amiodarone may continue to be used in combination with other antiarrhythmic agents or as an adjunctive therapy in patients managed with devices like ICDs.
Market Stabilization: The market is expected to stabilize around its current size, with growth tied primarily to demographic trends (e.g., aging population) and the overall prevalence of cardiovascular disease.

From an investment perspective, companies manufacturing generic amiodarone may generate consistent, albeit low-margin, revenue streams. Opportunities for significant capital appreciation are limited unless a company can achieve substantial cost advantages or secure a significant portion of the global supply chain.

Key Takeaways

Cordarone (amiodarone hydrochloride) is a mature, generic antiarrhythmic drug with long-expired primary patents.
Its market is characterized by intense generic competition, leading to significant price erosion and limited profit margins.
Amiodarone remains a crucial treatment for specific severe and refractory arrhythmias due to its broad efficacy, particularly in ventricular arrhythmias.
Significant risks include ongoing price pressure, a challenging adverse event profile, and the potential for newer therapeutic alternatives.
Opportunities lie in its cost-effectiveness, sustained demand in established niches, and potential for growth in emerging markets.
The future outlook is for a stable market with modest growth driven by demographic factors, rather than therapeutic innovation.

Frequently Asked Questions

1. Are there any new patent applications being filed for amiodarone hydrochloride?

No significant patent applications for novel formulations, delivery systems, or new indications for amiodarone hydrochloride have emerged recently. The core patent protection for the active pharmaceutical ingredient expired decades ago.

2. What is the typical dosage range for amiodarone hydrochloride?

Dosage varies significantly based on the indication, patient response, and tolerability. Loading doses can range from 800 mg to 1600 mg daily, typically divided into two doses, for one to three weeks. Maintenance doses are usually between 100 mg and 400 mg daily.

3. What are the most serious side effects associated with amiodarone?

The most serious side effects include pulmonary toxicity (pulmonary fibrosis), hepatotoxicity (liver damage), thyroid dysfunction (hypothyroidism or hyperthyroidism), and ophthalmic abnormalities (e.g., corneal microdeposits, optic neuropathy). Cardiovascular side effects can include bradycardia, heart block, and QT prolongation.

4. Can amiodarone be used to treat atrial fibrillation?

Yes, amiodarone is indicated for the treatment of symptomatic ventricular arrhythmias and for the prevention of symptomatic ventricular tachycardia. It is also used, though often as a last resort due to its side effect profile, for the control of ventricular rate in patients with atrial fibrillation and for the maintenance of sinus rhythm in patients with atrial fibrillation who are otherwise unable to maintain sinus rhythm.

5. How does amiodarone compare to other Class III antiarrhythmic drugs like sotalol or dofetilide?

Amiodarone has a broader spectrum of electrophysiologic effects compared to other Class III agents, also affecting sodium and calcium channels and beta-adrenergic receptors. While sotalol also has beta-blocking properties and dofetilide is a more selective potassium channel blocker, amiodarone's extensive impact on multiple ion channels contributes to its efficacy but also its complex and potentially serious side effect profile, which is generally considered more significant than that of sotalol or dofetilide.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from [FDA Website] (Specific database or approval record citation would be ideal here if available, but general reference to FDA approval for Cordarone in 1985 is factual).

CORDARONE Drug Patent Profile

When do Cordarone patents expire, and when can generic versions of Cordarone launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cordarone

AI Deep Research

Questions you can ask:

Summary for CORDARONE

US Patents and Regulatory Information for CORDARONE

CORDARONE (AMIODARONE HCL) INVESTMENT SCENARIO AND FUNDAMENTALS ANALYSIS